Abstract
New drugs are required to counter the tuberculosis (TB) pandemic. Here, we describe the synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse models of TB. Using genetics and biochemistry, we identified the enzyme decaprenylphosphoryl-beta-d-ribose 2'-epimerase as a major BTZ target. Inhibition of this enzymatic activity abolishes the formation of decaprenylphosphoryl arabinose, a key precursor that is required for the synthesis of the cell-wall arabinans, thus provoking cell lysis and bacterial death. The most advanced compound, BTZ043, is a candidate for inclusion in combination therapies for both drug-sensitive and extensively drug-resistant TB.
Original language | English |
---|---|
Journal | Science |
Volume | 324 |
Issue number | 5928 |
Pages (from-to) | 801-4 |
Number of pages | 4 |
DOIs | |
Publication status | Published - 8 May 2009 |
Keywords
- Amino Acid Sequence
- Animals
- Antitubercular Agents
- Arabinose
- Cell Wall
- Drug Resistance, Bacterial
- Enzyme Inhibitors
- Ethambutol
- Gene Expression Regulation, Bacterial
- Genes, Bacterial
- Mice
- Mice, Inbred BALB C
- Microbial Sensitivity Tests
- Molecular Sequence Data
- Molecular Structure
- Mycobacterium
- Mycobacterium tuberculosis
- Polysaccharides
- Racemases and Epimerases
- Spiro Compounds
- Thiazines
- Tuberculosis
- Journal Article
- Research Support, Non-U.S. Gov't